SNKTHERAPEUTICS.COM
Updated 3 days ago
S&K Therapeutics owns an AI (artificial intelligence) based drug development platform that allows to discover new molecular entities effectively. Furthermore, based on extensive research experience on TLRs (Toll-like receptors) and NLRP3 (NACHT, LRR, and PYD domains-containing protein 3), S&K therapeutics is establishing new drug development pipelines for autoimmune diseases, inflammatory diseases, and viral diseases.